Jaypirca® (Pirtobrutinib) Yovomerezeka ku China pochiza khansa ya m'magazi yobwerera m'mbuyo kapena yobwerera m'mbuyo kapena yaing'ono ya lymphocytic lymphoma

Kumayambiriro kwa mwezi wa Marichi, bungwe la National Medical Products Administration linavomereza Jaypirca® (pirtobrutinib) kuti igwiritsidwe ntchito pochiza odwala akuluakulu omwe ali ndi matenda a chronic lymphocytic leukemia (CLL) kapena small lymphocytic lymphoma (SLL) omwe adalandirapo chithandizo chimodzi cham'mbuyomu, kuphatikizapo Bruton's tyrosine kinase (BTK) inhibitor.

Pirtobrutinib ndi mankhwala oletsa kwambiri a kinase omwe amagwiritsa ntchito njira yatsopano yolumikizirana ndi mankhwala osagwirizana ndi covalent kuti awonjezere phindu lolunjika pa njira ya BTK mwa odwala a CLL/SLL omwe adachiritsidwa kale ndi mankhwala oletsa BTK (ibrutinib, acalabrutinib, kapena zanubrutinib). Pirtobrutinib idavomerezedwa ndi US FDA mu Januwale 2023 ngati mankhwala oletsa BTK omwe samagwirizana ndi covalent (osinthika). Mu Okutobala 2024, pirtobrutinib idavomerezedwa ku China ngati mankhwala amodzi ochizira odwala akuluakulu omwe ali ndi relaxed or refractory mantle cell lymphoma (MCL) omwe adalandirapo mankhwala osachepera awiri am'mbuyomu, kuphatikiza mankhwala oletsa Bruton's tyrosine kinase (BTK).

Kuvomerezedwa kwa chizindikiro chatsopanochi kumachokera ku zotsatira za kafukufuku wapadziko lonse wa BRUIN CLL 321 wa Gawo 3, wa m'malo osiyanasiyana, wosasankhidwa mwachisawawa. BRUIN CLL 321 ndiye mayeso oyamba padziko lonse lapansi a Gawo 3 osasankhidwa mwachisawawa omwe adachitidwa mwa odwala omwe ali ndi CLL/SLL omwe adathandizidwa kale ndi mankhwala oletsa BTK (cBTKi). Kafukufukuyu adalembetsa odwala 238 ndipo adawunika momwe pirtobrutinib imagwirira ntchito komanso chitetezo cha mankhwala amodzi poyerekeza ndi zomwe wofufuza adasankha IdelaR (idelalisib plus rituximab) kapena BR (bendamustine plus rituximab). Zotsatira zake zidawonetsa kuti pirtobrutinib idakulitsa kwambiri moyo wopanda kupulumuka kwapakati (PFS) poyerekeza ndi njira yosankhidwa ndi wofufuzayo (miyezi 14.0 vs miyezi 8.7; chiŵerengero cha zoopsa [HR] = 0.54). Kuphatikiza apo, kuchuluka kwa anthu omwe adasiya kugwiritsa ntchito mankhwala chifukwa cha zovuta zokhudzana ndi chithandizo kunali kotsika ndi pirtobrutinib (5.2% poyerekeza ndi 21.1%), zomwe zidathandizira kuti igwire bwino ntchito komanso kuti ipirire bwino odwala omwe adalandira kale mankhwala oletsa BTK.

Lumikizanani Nafe Kuti Muyambe Ulendo Wanu wa Chiyembekezo

Chipatala cha International Department of Beijing South Region Oncology Hospital chadzipereka kupatsa odwala apadziko lonse mwayi wopeza chithandizo chapamwamba kwambiri cha khansa. Ngati inu kapena wachibale wanu akukumana ndi matenda a khansa ndipo sanayankhe bwino mankhwala ochiritsira, gulu lathu la International Patient Services lili okonzeka kukupatsani zambiri mwatsatanetsatane komanso mapulani a chithandizo chapadera.

Chonde titumizireni uthenga kudzera m'njira zotsatirazi kuti mudziwe zambiri zokhudza njira zochizira khansa:

- Foni: 400-880-3716

- WeChat: 17801183037

-   Email: 100085_010@163.com or myimmnet@163.com (Emails are welcome, and we will respond promptly)

Chipatala cha International Department of Beijing South Region Oncology Hospital chikuyembekezera kugwira nanu ntchito yolimbana ndi khansa. Kaya muli kuti padziko lonse lapansi, tadzipereka kukupatsani chithandizo chamankhwala chaukadaulo komanso chisamaliro chachifundo.

Take the first step towards overcoming your illness. Call us at 400-880-3716 or contact us via WeChat at 17801183037 today. You can also email us at 100085_010@163.com or myimmnet@163.com to schedule a one-on-one consultation with our team of experts.